DMT-Assisted Therapy

Reviewed by the HeyPsych Medical Review Board

Board-certified psychiatrists and mental health professionals

Indications

Primary Indications

Treatment-resistant depressionGeneralized anxietyAddiction (alcohol, tobacco, other substances)Palliative/end-of-life distress

Mechanism

DMT is a serotonergic psychedelic primarily acting as a 5-HT2A receptor agonist, with additional activity at 5-HT1A and sigma-1 receptors. Its rapid onset triggers profound alterations in consciousness, perception, and emotional processing. Preclinical evidence suggests DMT enhances neuroplasticity, synaptogenesis, and stress resilience. In therapy, the psychedelic state may facilitate breakthroughs in cognition, emotional regulation, and therapeutic alliance.

Protocol

Preparation

Psychological screening, medical evaluation, therapeutic preparation.

Procedure

Administration of IV or IM DMT in a clinical/therapeutic environment
Acute monitoring during the 5–30 minute psychedelic state
Therapeutic support throughout the experience
Integration therapy session(s) following the psychedelic exposure

Frequency: Single or repeated sessions, depending on trial design

Duration: Core psychedelic effects last minutes; total therapeutic session ~1–2 hours

Total Treatment Time: Varies; often several sessions including prep and integration

Expected Outcomes

Immediate

Intense altered state of consciousness
Ego dissolution
Emotional release

Short Term

Rapid mood improvement
Reduced anxiety
Increased psychological flexibility

Long Term

Sustained antidepressant effects in some patients
Potential reduction in substance use
Improved existential outlook

Side Effects

common

Nausea
Anxiety
Increased heart rate
Elevated blood pressure

uncommon

Intense psychological distress
Transient confusion

rare

Persistent perceptual disturbances
Triggering psychotic episode in vulnerable individuals

Contraindications

absolute

History of schizophrenia or psychotic disorders
Severe uncontrolled cardiovascular disease

relative

Bipolar disorder
Use of serotonergic medications (risk of serotonin syndrome)

Patient Selection

ideal candidates

Adults with treatment-resistant depression
Patients in palliative care with end-of-life anxiety
Individuals with substance use disorders in structured programs

screening required

Medical clearance
Psychiatric evaluation
Medication review

Research Evidence

Key Studies

Phase I/II trials of IV DMT in depression showing safety and preliminary efficacy.
Preclinical studies showing rapid-acting antidepressant-like effects of DMT.
Comparisons with ayahuasca studies demonstrating potential for mood and addiction improvements.

Limitations

Limited sample sizes; short follow-up durations; optimal protocols (dose, frequency) not yet established.

Cost Considerations

typical session cost: Unknown; investigational only

total treatment cost: Projected to be moderate-to-high due to clinical monitoring

insurance coverage: Not covered; research context only

ux display: undefined

collapsible: undefined

heading: undefined

This treatment information is for educational purposes only. Treatment decisions should be made in consultation with qualified healthcare professionals based on individual circumstances, symptoms, and medical history. Do not attempt treatment without professional guidance.

Interested in this treatment?

This information is for educational purposes. Always consult with a qualified healthcare provider before starting any new treatment.

Locate Psychiatrists